Breast Ductal Carcinoma
Breast ductal carcinomas most frequently harbor alterations in TP53, PIK3CA, GATA3, ERBB2, and CCND1 .
PIK3CA Mutation, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and PIK3CA Codon 1047 Missense are the most common alterations in breast ductal carcinoma .
There is 1 clinical trial for breast ductal carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains breast ductal carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Lutetium lu 177-dtpa-omburtamab is the most common intervention in breast ductal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.